Friday, June 10, 2011  |  Volume 3/Number 5  |  A Production of the BioProcessing Journal

BPJ Now in Production
Tell us what you're
working on.
We can help you develop the best approach for publishing your work.
Contact us now!
Career Development
Case Studies in
Identifying and Correcting Failed Lyophilized Products

June 28, 2011
at 9:00 am & 2:00 pm EDT
Introduction to
Electron Microscopy
for Life Sciences
July 7, 2011
at 11:00 am EDT
Downstream Processing of Biotechnology Products
September 13-16, 2011
Logan, Utah USA
Receive 10% off the course registration when you mention promo code “ISBioTech.”
Suggested Reading
Development of Novel Transgenic Insect Cell Lines that
Support Humanized Glycoprotein Production by Baculovirus Expression Vectors
By Donald L. Jarvis, PhD, Jason R. Hollister, PhD, and Jared J. Aumiller,
Department of Molecular Biology, University of Wyoming
FDA Perspectives on Characterization and Comparability of Cellular Therapy Products
By Kimberly Benton, PhD, CBER/FDA
Sponsored Links
Lonza Viral-based Therapeutics Clean Room Expansion Plans

Lonza has announced it will expand its viral-based therapeutics business with the construction of a new, state-of-the-art cGMP clean room located adjacent to its existing Houston, Texas operations.

The clean room will benefit customers by offering large-scale capacity to support late-stage viral vaccine and gene therapy projects. It will utilize disposable process systems and be able to support production and fill/finish operations of up to 2,000 liters. Enhanced EU-compliant fill and finish capabilities are in high demand from Lonza's pharma and biotech customers. The expansion will also notably reduce Lonza's clients' wait times for clean room capacity due to the ability to run multiple GMP operations simultaneously.

"We are very pleased with the growing number of opportunities we are seeing in the viral vaccine and viral vector sector," said David Enloe, Head of Lonza's Viral-based Therapeutics unit. "This investment only furthers our commitment to a leadership position in this exciting space of new therapeutics and vaccines." Construction and validation of Lonza's viral expansion is expected to be completed in early 2012.

Sensirion AG launches the LG01 Micro Flow Switch and Bubble Detector for Liquids

The Swiss sensor manufacturer Sensirion AG has launched the LG01 micro flow switch to detect ultra-low liquid flow rates or the presence of air in fluidic systems. The sensor increases reliability by enabling the detection of liquid flow within the range of a few ml/min and less. For such measurements the sensor offers a short response time below 100 ms. Its output signal of either 0 or 5 volts indicates whether the current flow rate is above or below the specified flow switch level. Maximum flow rates are accepted up to 220 ml/min.

The tiny, lightweight sensor is designed for integration into bio-medical applications and general process control solutions.
Career Development
  Advertising & Media
  View Techno-Blast ad specifications by clicking here,
and then contact us for pricing.

And don't finalize your media plans for 2011-2012 without consulting our media kit!

BioProcessing Journal
and ISBioTech
BioProcessing Journal
and ISBioTech
ISBioTech on
  Techno-Blast Masthead
  This scanning electron micrograph of an immobilized hybridoma cell colony growing within the pores of chitosan-alginate fibers (day 15 of culture) was supplied by
Sandra E. Poole,
Genzyme Corporation.

Email your cell images to
the editor today!